ZA200106488B - N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance. - Google Patents

N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance.

Info

Publication number
ZA200106488B
ZA200106488B ZA200106488A ZA200106488A ZA200106488B ZA 200106488 B ZA200106488 B ZA 200106488B ZA 200106488 A ZA200106488 A ZA 200106488A ZA 200106488 A ZA200106488 A ZA 200106488A ZA 200106488 B ZA200106488 B ZA 200106488B
Authority
ZA
South Africa
Prior art keywords
insulin resistance
piperidinyl
propoxy
pyridine
hydroxy
Prior art date
Application number
ZA200106488A
Other languages
English (en)
Inventor
Maria Kuerthy
Katalin Biro
Karoly Nagy
Laszlo Uroegdi
Zita Csakai
Jenoe Szilbereky
Tamas Mogyorosi
Magdolna Toeroek
Andras Komaromi
Ede Marvanyos
Mihaly Barabas
Mihalyne Kardos
Zoltan Nagy
Laszlo Koranyi
Melinda Nagy
Original Assignee
Biorex Kutato Fejlesztoe Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutato Fejlesztoe Kft filed Critical Biorex Kutato Fejlesztoe Kft
Publication of ZA200106488B publication Critical patent/ZA200106488B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200106488A 1999-02-26 2001-08-07 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance. ZA200106488B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9900475A HUP9900475D0 (en) 1999-02-26 1999-02-26 O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component

Publications (1)

Publication Number Publication Date
ZA200106488B true ZA200106488B (en) 2002-08-07

Family

ID=90014224

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200106488A ZA200106488B (en) 1999-02-26 2001-08-07 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance.

Country Status (27)

Country Link
US (1) US6649628B1 (xx)
EP (1) EP1163224B1 (xx)
JP (1) JP4689838B2 (xx)
KR (1) KR100676124B1 (xx)
AT (1) ATE237590T1 (xx)
AU (1) AU779096B2 (xx)
BG (1) BG65178B1 (xx)
BR (1) BR0008969A (xx)
CA (1) CA2360451C (xx)
CZ (1) CZ297386B6 (xx)
DE (1) DE60002187T2 (xx)
DK (1) DK1163224T3 (xx)
EE (1) EE04961B1 (xx)
ES (1) ES2193055T3 (xx)
HR (1) HRP20010584B1 (xx)
HU (1) HUP9900475D0 (xx)
IL (2) IL144866A0 (xx)
NO (1) NO319793B1 (xx)
PL (1) PL197692B1 (xx)
PT (1) PT1163224E (xx)
RS (1) RS50083B (xx)
RU (1) RU2250901C2 (xx)
SI (1) SI1163224T1 (xx)
SK (1) SK287063B6 (xx)
UA (1) UA72495C2 (xx)
WO (1) WO2000050403A1 (xx)
ZA (1) ZA200106488B (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
BR0306778A (pt) * 2002-01-11 2004-12-28 Biorex Kutato Fejlesztoe Kft Derivados de carboxamidina e seu uso no tratamento de doenças vasculares
HUP0303584A3 (en) * 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
WO2008039514A1 (en) * 2006-09-26 2008-04-03 Cytrx Corporation Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration
BRPI0914684C1 (pt) 2008-06-26 2021-05-25 Orphazyme As uso de hsp70 ou um fragmento funcional ou variante do mesmo, e, hsp70 ou um fragmento funcional ou variante do mesmo
CN102215842A (zh) 2008-11-18 2011-10-12 参天制药株式会社 含有吡啶-3-甲醛o-(哌啶-1-基-丙基)-肟衍生物作为有效成分的脉络膜视网膜变性疾病的治疗剂
WO2012072082A1 (en) 2010-11-30 2012-06-07 Orphazyme Aps Methods for increasing intracellular activity of hsp70
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
ES2691981T3 (es) * 2012-09-06 2018-11-29 Mcpharma Biotech Inc. Tratamiento de la diarrea y de la diarrea post-destete con almidón resistente de patata
KR101768784B1 (ko) 2012-09-14 2017-08-16 쌩-고벵 글래스 프랑스 전기 접속 요소를 갖는 판유리
WO2015015248A1 (en) * 2013-07-30 2015-02-05 Debreceni Egyetem 67% The use of compounds showing heat shock protein (hsp) co-inducing properties to enhance the insulin sensitizing effect in the treatment of type 2 diabetes
PL3193840T3 (pl) * 2014-09-15 2021-12-06 Orphazyme A/S Preparat arimoklomolu
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
HUE052158T2 (hu) 2016-04-29 2021-04-28 Orphazyme As Arimoklomol a glükocerebroszidázzal társult rendellenességek kezeléséhez
US20200085812A1 (en) 2017-05-24 2020-03-19 Orphazyme A/S Heat shock protein inducers and frontotemporal disorders
MX2020012480A (es) 2018-05-28 2021-03-25 Orphazyme As Niveles de la proteina de choque termico 70 (hsp70) en las muestras de celulas mononucleares de la sangre periferica (pbmc) como biomarcador para enfermedades.
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
WO2021116487A1 (en) 2019-12-13 2021-06-17 Som Innovation Biotech, S.A. Compounds for use in the treatment of niemann-pick c disease
MX2023000033A (es) 2020-06-24 2023-04-10 Kempharm Denmark As Arimoclomol para tratar la enfermedad de gaucher.
CA3202568A1 (en) * 2020-11-19 2022-05-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
CA3205873A1 (en) 2020-12-24 2022-06-30 Zevra Denmark A/S Arimoclomol for the treatment of niemann pick disease, type c, in patients with er type missense mutations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207988B (en) 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUT78138A (hu) * 1995-12-22 2000-09-28 BIOREX Kutató és Fejlesztő Rt Hidroximsavszármazékot tartalmazó készítmény a növénytermesztés elősegítésére és alkalmazása
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HU220971B1 (hu) 1997-04-03 2002-07-29 BIOREX Kutató és Fejlesztő Rt. Eljárás 0-(3-amino-2-hidroxi-propil)-hidroximsav-halogenidek előállítására
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké

Also Published As

Publication number Publication date
AU3182400A (en) 2000-09-14
UA72495C2 (uk) 2005-03-15
BG65178B1 (bg) 2007-05-31
NO20014103D0 (no) 2001-08-23
PL350915A1 (en) 2003-02-10
JP2002537384A (ja) 2002-11-05
CA2360451C (en) 2011-01-04
DE60002187D1 (de) 2003-05-22
JP4689838B2 (ja) 2011-05-25
YU60301A (sh) 2004-05-12
KR20010102410A (ko) 2001-11-15
DE60002187T2 (de) 2003-12-11
BG105837A (en) 2002-03-29
WO2000050403A1 (en) 2000-08-31
BR0008969A (pt) 2001-11-27
NO319793B1 (no) 2005-09-12
CZ297386B6 (cs) 2006-11-15
KR100676124B1 (ko) 2007-01-31
EP1163224B1 (en) 2003-04-16
SI1163224T1 (en) 2003-08-31
HRP20010584A2 (en) 2002-08-31
RS50083B (sr) 2009-01-22
ATE237590T1 (de) 2003-05-15
IL144866A0 (en) 2002-06-30
IL144866A (en) 2007-07-04
EP1163224A1 (en) 2001-12-19
ES2193055T3 (es) 2003-11-01
PL197692B1 (pl) 2008-04-30
CA2360451A1 (en) 2000-08-31
EE200100447A (et) 2002-12-16
AU779096B2 (en) 2005-01-06
RU2250901C2 (ru) 2005-04-27
CZ20013053A3 (cs) 2002-01-16
SK287063B6 (sk) 2009-10-07
HUP9900475D0 (en) 1999-04-28
NO20014103L (no) 2001-10-22
PT1163224E (pt) 2003-07-31
DK1163224T3 (da) 2003-08-04
EE04961B1 (et) 2008-02-15
US6649628B1 (en) 2003-11-18
HRP20010584B1 (en) 2010-08-31
SK11582001A3 (sk) 2001-12-03

Similar Documents

Publication Publication Date Title
IL144866A0 (en) N- [2-hydroxy-3- (1-piperidinyl) propoxy] pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance
GB0223038D0 (en) Therapeutic compounds
GB0225474D0 (en) Therapeutic agents
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
DE59410052D1 (de) Verwendung von nona- und dekapeptiden zur herstellung eines arzneimittels zur bekämpfung von aids
CA2361834A1 (en) Offset ablation profiles for treatment of irregular astigmatism
NZ504258A (en) Exendin 3 and 4 agonist compounds for the treatment of diabetes
IL138723A0 (en) Antitumor agent
HK1086489A1 (en) A nutrient pharmaceutical formulation comprising polyphenols and use in the manufacture of a medicament for the treatment of cancer
WO1999063977A3 (en) Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone, triazolam and brotizolam for treating or preventing sleep disorders
RU2001126126A (ru) N-[2-гидрокси-3-(1-пиперидинил)пропокси]пиридин-1-оксид-3-карбоксиимидоилхлорид и его применение при лечении невосприимчивости к инсулину
HK1047707A1 (zh) (+)-曲馬朵、o-去甲曲馬朵或(+)-o-去甲曲馬朵、o-去甲-n-單-去甲-曲馬朵或(+)-o-去甲-n-單-去甲-曲馬朵治療尿失禁的用途
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
AU7040201A (en) A new use for deferiprone
RS52011B (sr) Nova primena derivata taksoida
HK1045524B (zh) 具有抗痴呆作用的5-羥皂草苷配基衍生物
TNSN99138A1 (fr) Une composition antioxydante, cytostatique et a support energetique qui ameliore l'utilisation metabolique du glucose
AU3600199A (en) A pharmaceutical composition containing ezrin mutated on tyrosine 353
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
MY129832A (en) Substituted thiophenes, processes for their preparation, their use as medicament or diagnostic and medicament comprising them
TR200101980T2 (tr) Arilalkanoil türevleri, bunların preparasyon işlemleri
TR200200987T2 (tr) Kanser tedavisine yönelik,ornatılmış pirroller
WO1999051216A3 (en) 3-pyridyloxyalkylamine or aryloxyalkylamine derivatives as cholinergic agonists
ZA200102727B (en) Method of treating sickle cell disease or thalassemia.